Study on Antiviral Activities of Glycyrrhizin

Changchao Huan1,2,3, Chunqin Chen1,2,3, Weiyin Xu1,2,3, Tingting Guo4, Haochun Pan1,2,3, Song Gao1,2,3, *

1Institutes of Agricultural Science and Technology Development, College of Veterinary Medicine, Yangzhou University, Yangzhou, China
2Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China
3Key Laboratory of Avian Bioproduct Development, Ministry of Agriculture and Rural Affairs, Yangzhou, China
4College of Medicine, Yangzhou University, Yangzhou, China

Email address: changchao.huan@yzu.edu.cn (Changchao Huan), 1743090818@qq.com (Chunqin Chen), 1670921845@qq.com (Weiyin Xu), 849312088@qq.com (Haochun Pan), tingtingguo1989@163.com (Tingting Guo), gsong@yzu.edu.cn (Song Gao)

*Corresponding author

To cite this article:
Changchao Huan, Chunqin Chen, Weiyin Xu, Tingting Guo, Haochun Pan, Song Gao. Study on Antiviral Activities of Glycyrrhizin. International Journal of Biomedical Engineering and Clinical Science. Vol. 6, No. 4, 2020, pp. 68-70. doi: 10.11648/j.ijbecs.20200604.11

Received: October 16, 2020; Accepted: September 2, 2020; Published: November 9, 2020

Abstract: Licorice has been a common Chinese medicine for thousands of years, which has good medicinal value and nutritional value. It is widely applied to traditional Chinese medicine. Many studies have shown that licorice contains more than 20 triterpenoids and nearly 300 flavonoids. According to the literature, licorice has many activities such as antibacterial, antiviral, antioxidant, and antitumor. It not only directly inactivates the virus, but also inhibits its adsorption. However, glycyrrhizin, glycyrrhetinic acid, glycyrrhiza polysaccharide and glycyrrhiza flavonoids are the main components of licorice which possess antiviral and antimicrobial activities. Among them, glycyrrhizin has many pharmacological activities, such as antiviral, anti-inflammatory, anti-tumor, antibacterial and many other activities. This paper provides a summary of antiviral activities of glycyrrhizin. This active ingredient and possible mechanisms are summarized in detail. The results showed that glycyrrhizin was widely used in antiviral field, but its material basis and mechanism of action were not perfect and unified. A large number of literatures about glycyrrhizin anti-virus were reviewed and analyzed, and it was suggested that more different ways should be adopted to study it, so as to provide a broader theoretical basis for developing new antivirus drugs of glycyrrhizin. It is hoped that this review will be helpful to further study the potential therapeutic effect of glycyrrhizin as an antiviral drug.

Keywords: Glycyrrhizin, Antiviral, Chinese Medicine

1. Introduction

Glycyrrhizin (GL) is a triterpenoid saponin, one of the main compounds isolated from the roots of licorice. GL contains one molecule of glycyrrhetic acid, with structural similarities to hydrocortisone, and two molecules of glucuronic acid. GL has been shown that several beneficial pharmacological activities, including anti-inflammatory activity [1], anti-tumor activity [2], anti-allergic activities [3], and antiviral activities [4]. In recent years, there have been more and more research reports on the antiviral activity of GL, such as hepatitis C virus (HCV), human immunodeficiency virus (HIV), duck hepatitis Virus (DHV), severe acute respiratory syndrome coronavirus (SARS-COV) and so on.

2. Antiviral Activities of GL and Possible Mechanisms

2.1. HCV

Ashfaq et al. reported that at the concentration of 14.2 µg/ml, GL inhibited the titer of hepatitis C virus by inhibiting the expression of full-length virus particles and its core genes, and reduced hepatitis C virus by 50% [5]. At 40µg/ml concentration, viral inhibition of GL reached up to 89%. And Matsumoto et al. reported that GL inhibits the release of
hepatitis C virus, but not assembly and budding [5].

2.2. HIV

GL can induce interferon, enhance the function of NK cells and inhibit HIV replication. According to Takei et al. [6], GL can inhibit the infection of R5 HIV virus and the expression of CCL2 or IL-10 coreceptor CCR5. And GL inhibits the production of CCL2/IL-10 by polymorphonuclear neutrophils (PMN) stimulated by R5 HIV and inhibits the PMN-dependent increase of R5-HIV replication in monocyte-derived macrophages (MDMs) [7].

2.3. PEDV

Huan et al. reported that porcine epidemic diarrhea virus (PEDV) infection caused release of high mobility group box-1 (HMGB1), and that the HMGB1 competitive inhibitor GL inhibits PEDV infection and attenuated proinflammatory responses [8]. GL prevents binding HMGB1 to toll-like receptor 4 (TLR4) to inhibit PEDV infection, and this effect depends on the HMGB1/TLR4-MAPK p38 pathway [9].

2.4. PRRSV

According to Duan et al [10], GL is also effective against the porcine reproductive and respiratory syndrome virus (PRRSV, an enveloped single positive-strand RNA virus, Arterivirus), and their results showed that GL significantly reduced PRRSV proliferation and PRRSV-encoded protein expression in a dose-dependent manner.

2.5. HSV

Herpes simplex virus (HSV) is a neurotropic DNA virus, which can induce a variety of diseases including infection of central nervous system, mucocutaneous infections and occasionally infections of visceral organs. According to some reported studies, GL can inhibit adhesion between PMN and cerebral capillary vessel endothelial cells (CCEC) and thus playing a beneficial therapeutic role during HSV infection [11].

2.6. H5N1

GL inhibits the replication of highly pathogenic H5N1 influenza A virus, apoptosis induced by H5N1, and H5N1-induced expression of pro-inflammatory cytokines CXCL10, IL-6, CCL2, and CCL5 in lung-derived A549 cells. GL does not affect the expression of cytokines in uninfected cells, but inhibited the expression of all cytokines studied in H5N1 infected cells in a dose-dependent manner [12, 13]. Moreover, activation of NF-kB, MAPKs p38, and JNK has been associated with influenza A virus replication and virus-induced pro-inflammatory gene expression [14-16].

2.7. SARS-CoV

In addition to inhibition virus replication, GL inhibits adsorption and penetration of the virus at the early stage of replication cycle. The effect of adding GL during adsorption is not as good as adding after virus adsorption (EC50 600 mg/L vs 2400 mg/L, respectively). GL is most effective when given both during and after the adsorption period (EC50 300 mg/L) [17]. Through the introduction of certain chemical modifications, it is proved that it is possible to increase the antiviral efficacy of GL, but as these modifications also increase the cytotoxicity. The selectivity index of GL derivatives is reduced as compared with that of GL (selectivity index: ≥65) [18].

3. Recent Advances in Antiviral Activity of Glycyrrhizin

SARS-CoV-2 (COVID-19)

The recent pandemic 2019 novel coronavirus, also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [19]. It has been found that the severity of SARS-CoV-2 infection ranges from asymptomatic to mild respiratory infections, and then to severe to fatal pneumonia. At present, there is no vaccine or specific treatment for this novel virus. Therefore, it is urgent to put forward new treatment interventions for COVID-19.

Some studies have shown that reducing angiotensin converting enzyme 2 (ACE2) expression can reduce the number of access points of the virus to the body during the primary infection and potentially the spread inside the body [20]. GL is metabolized in the human body into glycyrrhetinic acid (GA). GA primarily inhibits an enzyme called 11-beta-hydroxysteroid dehydrogenase (11bHSD), both type 1 and 2. 11bHSD2 is an inhibition of this enzyme leads to an aldosterone like activation of MR via cortisol and may resemble the effects of high aldosterone levels in these organs. Interesting, high aldosterone levels lead to a down-regulation of ACE2 in the kidney [21]. Moreover, recent studies have shown that GL has the potential to bind directly to ACE2 and affect the expression of ACE2. GL may still be considered as a potential treatment for COVID-19 as it has an antiviral effect on SARS-CoV (ACE2 is also a functional receptor for the SARS-CoV) [22].

4. Discussion and Conclusion

Presently we have summarized the antiviral activities of GL. Many studies reveal that GL is responsible for the antiviral activities through different mechanisms. Antiviral effects of GL on early steps in the viral lifecycle, for example the inhibition of endocytosis of influenza A virus, the direct fusion of HIV, the virus entry and replication of SARS and PEDV. Then, GL inhibits HCV full length viral particle and HCV core gene expression both at RNA and protein level and has synergistic effect with interferon. GL can be used as an immunomodulatory agent against virus infection since GL treatment attenuates the production of some cytokines. GL may be capable to reduce the expression of ACE2 in the lung and lung inflammation, relieve lung symptoms, so it is helpful to treat respiratory diseases.

At present, the COVID-19 is still serious. We hope this
study be helpful to the research of GL treating COVID-19.

Acknowledgements

This research was funded by the National Natural Science Foundation of China (31902253), the Natural Science Foundation of Jiangsu Province (BK20180921), the individual technology research and development of modern agricultural industry of Jiangsu Province (CX (19) 3024), the China Postdoctoral Science Foundation (2018M632399), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the earmarked fund for Jiangsu Agricultural Industry Technology System.

References

[1] Y. Fujisawa, M. Sakamoto, M. Matsushita, T. Fujita, K. Nishioka, Glycyrrhizin inhibits the lytic pathway of complement–possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis, Microbiol Immunol 44 (2000) 799-804. 10.1111/j.1348-0421.2000.tb02566.x.

[2] H. Hibasami, H. Iwase, K. Yoshioka, H. Takahashi, Glycyrrhetic acid (a metabolite substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelocytic leukemia and stomach cancer cells, Int J Mol Med 17 (2006) 215-219.

[3] H. Inoue, T. Mori, S. Shibata, H. Saito, Pharmacological activities of glycyrrhetinic acid derivatives: analgesic and anti-type IV allergic effects, Chem Pharm Bull (Tokyo) 35 (1987) 3888-3893. 10.1248/cpb.35.3888.

[4] R. Pompei, O. Flore, M. A. Marcials, A. Panì, B. Loddo, Glycyrrhizin acid inhibits virus growth and inactivates virus particles, Nature 281 (1979) 689-690. 10.1038/281689a0.

[5] Y. Matsumoto, T. Matsuura, H. Aoyagi, M. Matsuda, S. S. Hmwe, T. Date, N. Watanabe, K. Watsuki, R. Suzuki, S. Ichinose, K. Wake, T. Suzuki, T. Miyamura, T. Wakita, H. Aizaki, Antiviral activity of glycyrrhizin against hepatitis C virus in vitro, PLoS One 8 (2013) e68992. 10.1371/journal.pone.0068992.

[6] M. Takei, M. Kobayashi, X. D. Li, R. B. Pollard, F. Suzuki, Glycyrrhizin inhibits R5 HIV replication in peripheral blood monocytes treated with 1-methyladenosine, Pathobiology 72 (2005) 117-123. 10.1159/000084414.

[7] T. Yoshida, M. Kobayashi, X. D. Li, R. B. Pollard, F. Suzuki, Inhibitory effect of glycyrrhizin on the neutrophil-dependent increase of R5 HIV replication in cultures of macrophages, Immunol Cell Biol 87 (2009) 554-558. 10.1038/icc.2009.40.

[8] C. C. Huan, H. X. Wang, X. X. Sheng, R. Wang, X. Wang, X. Mao, Glycyrrhizin inhibits porcine epidemic diarrhea virus infection and attenuates the proinflammatory responses by inhibition of high mobility group box-1 protein, Archives of virology 162 (2017) 1467-1476. 10.1007/s00705-017-3259-7.

[9] R. Gao, Y. Zhang, Y. Kang, W. Xu, L. Jiang, T. Guo, C. Huan, Glycyrrhizin Inhibits PEDV Infection and Proinflammatory Cytokine Secretion via the HMGB1/TLR4-MAPK p38 Pathway, Int J Mol Sci 21 (2020). 10.3390/ijms21082961.

[10] E. Duan, D. Wang, L. Fang, J. Ma, J. Luo, H. Chen, K. Li, S. Xiao, Suppression of porcine reproductive and respiratory syndrome virus proliferation by glycyrrhizin, Antiviral Res 120 (2015) 122-125. 10.1016/j.antiviral.2015.06.001.

[11] W. Huang, X. Chen, Q. Li, P. Li, G. Zhao, M. Xu, P. Xie, Inhibition of intercellular adhesion in herpex simplex virus infection by glycyrrhizin, Cell Biochem Biophys 62 (2012) 137-140. 10.1007/s12013-011-9271-8.

[12] M. Michaelis, J. Geiler, P. Naczek, P. Sithisarn, H. Ogbomo, B. Altenbrandt, A. Leutw, H. W. Doerr, J. Cinatl, Jr., Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced pro-inflammatory cytokine and chemokine expression in human macrophages, Med Microbiol Immunol 199 (2010) 291-297. 10.1007/s00430-010-0155-0.

[13] M. Michaelis, J. Geiler, P. Naczek, P. Sithisarn, A. Leutw, H. W. Doerr, J. Cinatl, Jr., Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression, PLoS One 6 (2011) e19705. 10.1371/journal.pone.0019705.

[14] J. Geiler, M. Michaelis, P. Naczek, A. Leutw, K. Langer, H. W. Doerr, J. Cinatl, Jr., N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus, Biochim Pharmacol 79 (2010) 413-420. 10.1016/j.bcp.2009.08.025.

[15] K. Kujime, S. Hashimoto, Y. Gon, K. Shimizu, T. Horie, p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells, J Immunol 164 (2000) 3222-3228. 10.4049/jimmunol.164.6.3222.

[16] S. Ludwig, Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy, J Antimicrob Chemother 64 (2009) 1-4. 10.1093/jac/dkp161.

[17] J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, H. W. Doerr, Glycyrrhizin, an active component of licorice roots, and replication of SARS-associated coronavirus, Lancet 361 (2003) 2045-2046. 10.1016/s0140-6736(03)13615-x.

[18] G. Hoever, L. Baltina, M. Michaelis, R. Kondratenko, L. Baltina, G. A. Tolstikov, H. W. Doerr, J. Cinatl, Jr., Antiviral activity of glycyrrhizin acid derivatives against SARS-coronavirus, J Med Chem 48 (2005) 1256-1259. 10.1021/jm0493008.

[19] Y. Zhou, Y. Hou, J. Shen, Y. Huang, W. Martin, F. Cheng, Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discov 6 (2020) 14. 10.1038/s41421-020-0153-3.

[20] H. Murck, Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?, Front Immunol 11 (2020) 1239. 10.3389/fimmu.2020.01239.

[21] S. Fukuda, C. Horimai, K. Harada, T. Wakamatsu, H. Fukasawa, S. Muto, A. Itai, M. Hayashi, Aldosterone-induced kidney injury is mediated by NFκB activation, Clin Exp Nephrol 15 (2011) 41-49. 10.1007/s10157-010-0371-8.

[22] J. H. Kuhn, W. Li, H. Choe, M. Farzan, Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus, Cell Mol Life Sci 61 (2004) 2738-2743. 10.1007/s00018-004-4242-5.